For many biopharma teams, Phase III is treated as the final mountain to climb. Once efficacy and safety are proven, commercial readiness is assumed to follow naturally. In reality, that assumption is one of the most costly missteps in drug development. More assets than ever... Continue reading
Return to previous page
Tag: Biopharma Launch Strategy
Japan has quietly turned its HTA framework into one of the most influential, but often misunderstood, pricing systems in major markets. Since formal cost-effectiveness evaluation became part of the NHI price-setting process in 2019, the country has refined its approach almost every year. The 2024-25... Continue reading